Skip to content

Study · Randomized controlled trial · n = 81 · 1995

2 results

Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.

Overgaard K, Lindsay R, Christiansen C

Clinical therapeutics1 Jul 1995Cited by 16 (Europe PMC)

PMID8565031 (opens in a new tab)DOI10.1016/0149-2918(95)80044-1 (opens in a new tab)PepBankPUB-08565031
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with low bone mass, salmon calcitonin reduced bone loss risk versus placebo, with relative risk 0.19 and 81% risk reduction.

    In plain wordsIn postmenopausal women with low bone mass, salmon calcitonin reduced bone loss risk versus placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseRisk of bone loss
    Study

    n = 81

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/d · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Relative risk
    0.19
    bone loss
    95% CI lower
    0.07
    bone loss
    95% CI upper
    0.5
    bone loss
    Risk reduction
    81%
    bone loss
    Patients who lost bone mass
    25 patients
    placebo
    Proportion who lost bone mass
    63%
    placebo
    P
    0.001
    between groups

    Source sentences

    Summary
    The relative risk of bone loss for patients receiving calcitonin salmon nasal spray was 0.19 (95% confidence interval, 0.07 to 0.50), representing an 81% risk reduction.
    3 context sentences
    Summary · context
    Of 40 valid completers who received placebo, 25 (63%) lost bone mass (P = 0.001 between groups).
    Summary · context
    A subanalysis of results from a randomized, double-blind, placebo-controlled, parallel-group, 2-year study was conducted to evaluate the response of individual patients to therapy with 200 IU/d calcitonin salmon nasal spray compared with placebo in postmenopausal women who had low bone mass.
    Summary · context
    All patients received 500 mg/d of oral supplemental calcium.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with low bone mass, 31 of 41 salmon calcitonin completers (76%) increased lumbar vertebral BMD.

    In plain wordsIn postmenopausal women with low bone mass, 76% of salmon calcitonin completers increased spine bone density.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasePositive BMD response
    Study

    n = 41

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/d · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Responders
    31 patients
    calcitonin
    Response proportion
    76%
    calcitonin

    Source sentences

    Summary
    Of 41 valid completers (ie, patients who met the entry criteria, were compliant with the protocol, and completed the study) treated with calcitonin salmon nasal spray, 31 (76%) responded positively to treatment.
    3 context sentences
    Summary · context
    A response to therapy was defined as an increase from baseline in lumbar vertebral bone mineral density, measured by use of dual-energy x-ray absorptiometry, at the end of 2 years of treatment.
    Summary · context
    A subanalysis of results from a randomized, double-blind, placebo-controlled, parallel-group, 2-year study was conducted to evaluate the response of individual patients to therapy with 200 IU/d calcitonin salmon nasal spray compared with placebo in postmenopausal women who had low bone mass.
    Summary · context
    All patients received 500 mg/d of oral supplemental calcium.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.